Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.38 |
| ▸ | NPY1R | P25929 | 10/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.38 |
| ▸ | NPY2R | P49146 | 6/20 | 0.38 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29539785 | 0.99 | NPY4R (0.38) | NPY4RNPY1RNPY5RNPY2RSLC15A2 | |
| SCHEMBL30974329 | 0.93 | FOLH1 (0.42) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL29485118 | 0.92 | FURIN (0.40) | NPY4RNPY1RNPY5RNPY2RSLC15A2 | |
| SCHEMBL30577044 | 0.91 | NMT2 (0.41) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL29485119 | 0.91 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL29485113 | 0.88 | ENPEP (0.43) | — | |
| SCHEMBL29740225 | 0.87 | NOD1 (0.46) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL29540259 | 0.87 | NOD1 (0.46) | NPY4RNPY1RNPY5RNPY2RNOD1 | |
| SCHEMBL29414400 | 0.86 | NPY4R (0.43) | NPY4RNPY1RNPY5RNPY2RSLC15A2 | |
| SCHEMBL29540572 | 0.86 | NPY4R (0.39) | NPY4RNPY1RNPY5RNPY2RNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372525-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | ARARIS BIOTECH AG (CH) | 2023-11-23 | — | — | US | disclosed |
| EP-4213886-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | Araris Biotech AG (CH) | 2023-07-26 | — | — | EP | disclosed |
| CN-116406302-A | Method of transglutaminase conjugation with amino acid based linkers | 阿拉里斯生物技术股份公司 | 2023-07-07 | — | — | CN | disclosed |
| WO-2022058594-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | ARARIS BIOTECH AG (CH) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372525-A1 | TRANSGLUTAMINASE CONJUGATION METHOD WITH AMINO ACID-BASED LINKERS | SP1, GLUL, TGM2 | NPY4R 2029/4885NPY1R 1911/4885NPY5R 2368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.